AbbVie announced positive topline results from the Phase IIIb/IV head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (Rinvoq) 15 mg, once daily, compared to adalimumab (Humira)… read more.
1 in 100 people in Britain today live with rheumatoid arthritis (RA). Unlike osteoarthritis (OA), RA is caused not by wear and tear but by the body’s immune… read more.
A study by scientists at the University of Colorado Anschutz Medical Campus reveals that joint tissue from patients with early-stage rheumatoid arthritis often have high levels of a… read more.
The most comprehensive analysis of rheumatoid arthritis data to date reveals that demographic changes and uneven health infrastructure have exacerbated the rheumatoid arthritis burden since 1980 and shows… read more.
Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a… read more.
In recent years treatment with powerful biologic and targeted synthetic therapies has changed the landscape for arthritis, but currently finding the right treatment for each person is a… read more.
Currently there are no cures for rheumatoid arthritis (RA) which affects 40,000 people in Ireland. The disease costs an estimated €20,000 per patient, per year with an overall… read more.
Treatment for rheumatoid arthritis (RA) has come a long way in recent years. In many cases, a battery of medications can now successfully stymy the inflammatory cells that… read more.
Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH announced that they have obtained manufacturing and marketing approval from the… read more.
Obesity is associated with worse flare symptoms and worse quality of life among patients with early rheumatoid arthritis, researchers reported on Nov. 12, 2023 at ACR Convergence 2023,… read more.
New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that treating rheumatoid arthritis with hydroxychloroquine (HCQ) reduced the risk of nonalcoholic fatty… read more.
Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca business to Alfasigma, including the European and UK… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
